Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to access the efficacy, tolerability and safety of RKI983
(0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients
with POAG or ocular hypertension.